Reinhart Partners Inc. Invests $4.15 Million in Enhabit, Inc. (NYSE … – MarketBeat


Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Reinhart Partners Inc. bought a new position in shares of Enhabit, Inc. (NYSE:EHABGet Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 295,799 shares of the company’s stock, valued at approximately $4,153,000. Reinhart Partners Inc. owned approximately 0.60% of Enhabit as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in EHAB. CI Investments Inc. purchased a new position in Enhabit during the 2nd quarter worth approximately $27,000. Klingman & Associates LLC purchased a new position in Enhabit during the 3rd quarter worth approximately $211,000. Millennium Management LLC purchased a new position in Enhabit during the 2nd quarter worth approximately $230,000. Louisiana State Employees Retirement System purchased a new position in Enhabit during the 3rd quarter worth approximately $333,000. Finally, Maryland State Retirement & Pension System purchased a new position in Enhabit during the 3rd quarter worth approximately $340,000. Institutional investors and hedge funds own 95.55% of the company’s stock.

Insider Buying and Selling at Enhabit

In related news, Director Jeffrey Bolton bought 2,000 shares of the firm’s stock in a transaction dated Wednesday, November 9th. The stock was bought at an average price of $12.75 per share, with a total value of $25,500.00. Following the completion of the transaction, the director now directly owns 14,597 shares of the company’s stock, valued at $186,111.75. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Gregory S. Rush acquired 8,300 shares of the business’s stock in a transaction on Monday, November 7th. The shares were purchased at an average price of $12.69 per share, for a total transaction of $105,327.00. Following the completion of the purchase, the director now directly owns 16,597 shares of the company’s stock, valued at approximately $210,615.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bolton bought 2,000 shares of the stock in a transaction dated Wednesday, November 9th. The shares were bought at an average cost of $12.75 per share, with a total value of $25,500.00. Following the completion of the acquisition, the director now directly owns 14,597 shares of the company’s stock, valued at approximately $186,111.75. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 13,000 shares of company stock valued at $164,903.

Analysts Set New Price Targets

A number of research firms recently issued reports on EHAB. Credit Suisse Group dropped their price target on Enhabit from $19.00 to $15.00 and set a “neutral” rating on the stock in a research note on Friday, November 4th. Stifel Nicolaus initiated coverage on Enhabit in a research note on Monday, December 5th. They issued a “buy” rating and a $17.00 target price on the stock. UBS Group initiated coverage on Enhabit in a research note on Thursday, December 8th. They issued a “sell” rating and a $12.00 target price on the stock. Oppenheimer initiated coverage on Enhabit in a research note on Thursday, October 13th. They issued a “market perform” rating on the stock. Finally, CJS Securities initiated coverage on Enhabit in a research note on Tuesday, December 13th. They issued a “market perform” rating and a $18.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $16.43.

Enhabit Stock Performance

EHAB stock traded up $0.08 during midday trading on Friday, hitting $13.35. 3,930 shares of the stock were exchanged, compared to its average volume of 583,138. Enhabit, Inc. has a fifty-two week low of $11.65 and a fifty-two week high of $25.25. The stock’s 50-day moving average is $13.27. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.50 and a current ratio of 1.50.
Enhabit (NYSE:EHABGet Rating) last released its quarterly earnings results on Tuesday, November 1st. The company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.09). The company had revenue of $265.70 million during the quarter, compared to analyst estimates of $265.62 million. Enhabit had a return on equity of 7.62% and a net margin of 7.76%. Sell-side analysts forecast that Enhabit, Inc. will post 1.45 earnings per share for the current fiscal year.

About Enhabit

(Get Rating)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

See Also

Want to see what other hedge funds are holding EHAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enhabit, Inc. (NYSE:EHABGet Rating).
Institutional Ownership by Quarter for Enhabit (NYSE:EHAB)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Enhabit, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Enhabit wasn’t on the list.
While Enhabit currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat’s analysts have just released their top five short plays for January 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Enter your email address below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2023 and why they should be in your portfolio.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
[email protected]
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

source


Leave a Reply

Your email address will not be published.